Evaluation of Serum Level and Tissue Expression of Galectin-7 in Patients with Hypertrophic Scars
E.M.K.Sanad1, N.E.Sorour1, A.A.El fallah2 and A.M.Elberber1"
Hypertrophic scars [HS] are benign fibrous growths characterized by excessive deposition of extracellular matrix at sites of prior dermal injury. Galectin-7 is thought to play a role during wound healing, functioning as a regulator of keratinocyte proliferation and migration that is central in maintaining and restoring epidermal homeostasis. So decrease in tissue expression and serum levels of galectin-7 may play a role in the pathogenesis of hypertrophic scars.The aim of the work is to evaluate serum level and tissue expression of galectin-7 in patients with hypertrophic scars compared with control subjects.this was a case control study, This study included 20 patients, suffering from hypertrophic scars [Group A]. In addition, 20 apparently healthy individuals of matched age and sex were chosen as a control group [Group B]. Patients were selected from the outpatient clinic of Dermatology and Andrology department of Banha University Hospitals in the period from January 2019 to April 2019, Serum and tissue level of Galectin-7 were measured using Human Galectin-7 ELISA Kit supplied by Biokit Company, China. Serum level and tissue expression of galectin-7 were found to be lower in HS Patients than control and Serum level of galectin-7 positively correlates with its tissue expression level, No statistical significant correlations between galectin-7 tissue expression level and age, or duration of the lesion [P>0.05 for all]. we concluded that that HS is associated with decreased tissue and serum levels of galectin-7. These results suggest that the differences in galectin-7 expression may be crucially involved in the pathogenic process of HS.
Galectin-7, Tissue, Dermatology, Hypertrophic, Scars.